Articles
BERLIN—The field of oncology has come a long way in improving communication between healthcare providers and their patients with cancer—that is, unless the patient happens to be an adolescent.
From diagnosis through treatment, profound deficits still remain in the care of this age group, according to several presentations at the Joint Congress of the European Cancer Organisation and European Society for Medical Oncology.
Read More ›Methylphenidate (MPH), a drug used to treat attention deficit hyperactivity disorder in healthy children also has long-term benefits for childhood cancer survivors, a new study indicates.
After 12 months of treatment with MPH, children showed significant improvements on measures of attention, social skills, and behavior compared with a control group of children who did not receive MPH.
Interventions targeted to family caregivers of patients with cancer have modest but significant positive effects on coping ability and other caregiver outcomes, a new meta-analysis indicates.
Adding two new biomarkers to a risk-prediction model allows enhanced identification of cancer patients at high or low risk of venous thromboembolism (VTE), according to a recent study published in Blood.
The US Food and Drug Administration (FDA) has approved a higher, more efficacious dose of fulvestrant (Faslodex, AstraZeneca) injection for treatment of metastatic breast cancer. The newly approved dose of 500 mg replaces the previously approved monthly dose of 250 mg for the treatment of hormone receptor–positive (HR+) metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
Deaths from ovarian cancer could drop by as much as 50% in the next 20 years if surgeons remove the fallopian tubes of women undergoing a hysterectomy or tubal ligation, according to a team of gynecologic oncologists from Vancouver General Hospital and the British Columbia Cancer Agency.
Multivitamin use during and after adjuvant chemotherapy did not reduce the risk of cancer recurrence or mortality in patients with stage III colon cancer, according to recently released findings of Cancer and Leukemia Group B (CALGB) 89803. Multivitamin use, however, also did not impact patients’ health negatively.
Researchers have developed a tool for predicting individualized risk of local recurrence after breast-conserving surgery (BCS) in women with ductal carcinoma in situ (DCIS). The tool integrates 10 clinicopathologic variables to assist patients and their healthcare professionals decide among various treatment options with the goal of reducing over- and undertreatment of noninvasive breast cancer.
Radiation therapy after local surgical therapy should be considered in patients with adenoid cystic carcinoma (ACC) of the breast who are otherwise eligible for radiation therapy, concluded a group of researchers from the University of California-Davis.